Cargando…

Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell Function

OBJECTIVE: To investigate the effect of exogenous as well as endogenous glucagon-like peptide 1 (GLP-1) on postprandial glucose excursions and to characterize the secretion of incretin hormones in type 1 diabetic patients with and without residual β-cell function. RESEARCH DESIGN AND METHODS: Eight...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kielgast, Urd, Holst, Jens J., Madsbad, Sten
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2011
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3292336/ https://www.ncbi.nlm.nih.gov/pubmed/21441444 http://dx.doi.org/10.2337/db10-1790

Ejemplares similares

Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell Function
por: Kielgast, Urd, et al.
Publicado: (2011)

Peripheral Mechanisms Mediating the Sustained Antidiabetic Action of FGF1 in the Brain
por: Scarlett, Jarrad M., et al.
Publicado: (2019)

GIP and GLP-1 Potentiate Sulfonylurea-Induced Insulin Secretion in Hepatocyte Nuclear Factor 1α Mutation Carriers
por: Christensen, Alexander S., et al.
Publicado: (2020)

FGF21 Analogs of Sustained Action Enabled by Orthogonal Biosynthesis Demonstrate Enhanced Antidiabetic Pharmacology in Rodents
por: Mu, James, et al.
Publicado: (2012)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

A Response to “The Relationship Between Sleep and Quality of Life in Type 1 Diabetes Patients”
por: Nørgaard, Kirsten, et al.
Publicado: (2019)

Quality of Life is Markedly Impaired by Rheumatological and Skin Manifestations in Patients with Type 1 Diabetes: A Questionnaire Survey
por: Nørgaard, Kirsten, et al.
Publicado: (2019)

Exenatide Protects Against Glucose- and Lipid-Induced Endothelial Dysfunction: Evidence for Direct Vasodilation Effect of GLP-1 Receptor Agonists in Humans
por: Koska, Juraj, et al.
Publicado: (2015)

Identification of a Small Molecular Insulin Receptor Agonist With Potent Antidiabetes Activity
por: Qiang, Guifen, et al.
Publicado: (2014)

Antidiabetic Effects of Pterosin A, a Small-Molecular-Weight Natural Product, on Diabetic Mouse Models
por: Hsu, Feng-Lin, et al.
Publicado: (2013)

Sustained Antidiabetic Effects of a Berberine-Containing Chinese Herbal Medicine Through Regulation of Hepatic Gene Expression
por: Zhao, Hai-Lu, et al.
Publicado: (2012)

Chronic GLP-1 Receptor Activation by Exendin-4 Induces Expansion of Pancreatic Duct Glands in Rats and Accelerates Formation of Dysplastic Lesions and Chronic Pancreatitis in the Kras(G12D) Mouse Model
por: Gier, Belinda, et al.
Publicado: (2012)

Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes
por: Lang, Shan, et al.
Publicado: (2020)

The effect of DPP-4-protected GLP-1 (7–36) on coronary microvascular function in obese adults
por: Nilsson, Malin, et al.
Publicado: (2019)

Enhancing endogenous levels of GLP1 dampens acute olanzapine induced perturbations in lipid and glucose metabolism
por: Medak, Kyle D., et al.
Publicado: (2023)

GIP Does Not Potentiate the Antidiabetic Effects of GLP-1 in Hyperglycemic Patients With Type 2 Diabetes
por: Mentis, Nikolaos, et al.
Publicado: (2011)

Minor Contribution of Endogenous GLP-1 and GLP-2 to Postprandial Lipemia in Obese Men
por: Matikainen, Niina, et al.
Publicado: (2016)

Postprandial Diabetic Glucose Tolerance Is Normalized by Gastric Bypass Feeding as Opposed to Gastric Feeding and Is Associated With Exaggerated GLP-1 Secretion: A case report
por: Dirksen, Carsten, et al.
Publicado: (2010)

Endogenous and Exogenous Vanilloids Evoke Disparate TRPV1 Activation to Produce Distinct Neuronal Responses
por: Kumar, Rakesh, et al.
Publicado: (2020)

The Mechanism of Metabolic Influences on the Endogenous GLP-1 by Oral Antidiabetic Medications in Type 2 Diabetes Mellitus
por: Nguyen, Thiquynhnga, et al.
Publicado: (2020)

Novel Trajectories of Bromocriptine Antidiabetic Action: Leptin-IL-6/ JAK2/p-STAT3/SOCS3, p-IR/p-AKT/GLUT4, PPAR-γ/Adiponectin, Nrf2/PARP-1, and GLP-1
por: Reda, Enji, et al.
Publicado: (2018)

Transgenic Overexpression of Galectin-3 in Pancreatic β Cells Attenuates Hyperglycemia in Mice: Synergistic Antidiabetic Effect With Exogenous IL-33
por: Jovicic, Nemanja, et al.
Publicado: (2021)

Antiaging Gene Klotho Attenuates Pancreatic β-Cell Apoptosis in Type 1 Diabetes
por: Lin, Yi, et al.
Publicado: (2015)

Fibroblast Growth Factor 21 Action in the Brain Increases Energy Expenditure and Insulin Sensitivity in Obese Rats
por: Sarruf, David A., et al.
Publicado: (2010)

Cross-sectional study on medicinal products without commercial interest (MPWCI) in the Spanish market
por: Esteve Sala, Emili, et al.
Publicado: (2019)

Effects of placebos without deception compared with no treatment: protocol for a systematic review and meta-analysis
por: Petkovic, Grace, et al.
Publicado: (2015)

Increased oral sodium chloride intake in humans amplifies selectively postprandial GLP‐1 but not GIP, CCK, and gastrin in plasma
por: Asmar, Ali, et al.
Publicado: (2020)

Discovery of URAT1 SNPs and association between serum uric acid levels and URAT1
por: Cho, Sung Kweon, et al.
Publicado: (2015)

Regulatory approval of pharmaceuticals without a randomised controlled study: analysis of EMA and FDA approvals 1999–2014
por: Hatswell, Anthony J, et al.
Publicado: (2016)

Slowed Metabolic Decline After 1 Year of Oral Insulin Treatment Among Individuals at High Risk for Type 1 Diabetes in the Diabetes Prevention Trial–Type 1 (DPT-1) and TrialNet Oral Insulin Prevention Trials
por: Sosenko, Jay M., et al.
Publicado: (2020)

Inhibition of 12/15-Lipoxygenase Protects Against β-Cell Oxidative Stress and Glycemic Deterioration in Mouse Models of Type 1 Diabetes
por: Hernandez-Perez, Marimar, et al.
Publicado: (2017)

Transient Receptor Potential Vanilloid 1 Activation Enhances Gut Glucagon-Like Peptide-1 Secretion and Improves Glucose Homeostasis
por: Wang, Peijian, et al.
Publicado: (2012)

GLP-1 Receptor Agonist Treatment in Morbid Obesity and Type 2 Diabetes Due to Pathogenic Homozygous Melanocortin-4 Receptor Mutation: A Case Report
por: Iepsen, Eva W., et al.
Publicado: (2020)

GLP-1 Receptor: A New Target for Sepsis
por: Yang, Fuxun, et al.
Publicado: (2021)

GLP-1 and Intestinal Diseases
por: Hunt, Jenna Elizabeth, et al.
Publicado: (2021)

Optimization of a Glucagon-Like Peptide 1 Receptor Antagonist Antibody for Treatment of Hyperinsulinism
por: Peterson, Sean M., et al.
Publicado: (2023)

Role of endogenous and exogenous antioxidants in risk of six cancers: evidence from the Mendelian randomization study
por: Zhu, Jiahao, et al.
Publicado: (2023)

What is Diabetes Remission?
por: Holst, Jens J., et al.
Publicado: (2021)

Adverse drug reactions, multimorbidity and polypharmacy: a prospective analysis of 1 month of medical admissions
por: Osanlou, Rostam, et al.
Publicado: (2022)

Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs)
por: Desouza, Cyrus, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_q1da1gdd2f2bge3ingun9dj5jk